Teleflex Incorporated (NYSE:TFX) Shares Bought by Boston Trust Walden Corp

Boston Trust Walden Corp lifted its holdings in shares of Teleflex Incorporated (NYSE:TFX - Free Report) by 3.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 294,614 shares of the medical technology company's stock after purchasing an additional 11,052 shares during the quarter. Boston Trust Walden Corp owned about 0.63% of Teleflex worth $52,435,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Cromwell Holdings LLC increased its stake in shares of Teleflex by 59.0% during the 3rd quarter. Cromwell Holdings LLC now owns 132 shares of the medical technology company's stock valued at $33,000 after acquiring an additional 49 shares during the last quarter. Avior Wealth Management LLC grew its stake in shares of Teleflex by 190.6% during the 3rd quarter. Avior Wealth Management LLC now owns 154 shares of the medical technology company's stock valued at $38,000 after buying an additional 101 shares during the period. Ashton Thomas Securities LLC acquired a new stake in shares of Teleflex during the 3rd quarter worth $40,000. True Wealth Design LLC raised its position in shares of Teleflex by 16,600.0% in the 3rd quarter. True Wealth Design LLC now owns 167 shares of the medical technology company's stock worth $41,000 after buying an additional 166 shares during the period. Finally, GAMMA Investing LLC raised its position in shares of Teleflex by 131.1% in the 3rd quarter. GAMMA Investing LLC now owns 171 shares of the medical technology company's stock worth $42,000 after buying an additional 97 shares during the period. Hedge funds and other institutional investors own 95.62% of the company's stock.

Analysts Set New Price Targets

TFX has been the subject of several research analyst reports. StockNews.com upgraded Teleflex from a "hold" rating to a "buy" rating in a research note on Thursday, November 28th. Mizuho dropped their target price on shares of Teleflex from $275.00 to $250.00 and set a "neutral" rating for the company in a research report on Friday, November 1st. Truist Financial reduced their price target on shares of Teleflex from $227.00 to $200.00 and set a "hold" rating on the stock in a research report on Wednesday, December 18th. Royal Bank of Canada dropped their price objective on shares of Teleflex from $275.00 to $245.00 and set an "outperform" rating for the company in a research report on Friday, November 1st. Finally, Needham & Company LLC restated a "hold" rating on shares of Teleflex in a report on Monday, December 16th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $252.50.

Teleflex Stock Down 1.4 %

Shares of TFX stock traded down $2.42 on Thursday, hitting $173.61. The stock had a trading volume of 456,117 shares, compared to its average volume of 521,926. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.39 and a current ratio of 2.42. Teleflex Incorporated has a 52-week low of $171.69 and a 52-week high of $256.85. The stock's 50 day moving average is $180.84 and its 200-day moving average is $211.88. The firm has a market capitalization of $8.06 billion, a price-to-earnings ratio of 34.51, a P/E/G ratio of 1.78 and a beta of 1.16.

Teleflex Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.